SCHEMBL6413554

SCHEMBL6413554

COc1ccc(NCCNc2cccc(F)c2)cc1OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.51
KMT2A Q03164 4/20 0.51
MAPT P10636 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MEN1 O00255 2/20 0.51
MRGPRX1 Q96LB2 2/20 0.50
C5AR1 P21730 2/20 0.49
LRRK2 Q5S007 1/20 0.49
CTSV O60911 2/20 0.48
CTSL P07711 2/20 0.48
ALDH1A1 P00352 3/20 0.48
ALOX12 P18054 2/20 0.48
SMPD1 P17405 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA1D P25100 1/20 0.48
ADRA1A P35348 1/20 0.48
ADRA1B P35368 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6376682 0.81 C5AR1 (0.54) LMNAKMT2AMAPTL3MBTL1MEN1
SCHEMBL4228617 0.81 FFAR1 (0.66) LMNAKMT2AMAPTL3MBTL1CTSV
SCHEMBL30002764 0.81 FFAR1 (0.66) LMNAKMT2AMAPTL3MBTL1CTSV
SCHEMBL6412979 0.81 CTSV (0.51) LMNAKMT2AMAPTL3MBTL1MEN1
Hydrochloric Acid SCHEMBL28464909 0.80 C5AR1 (0.53) LMNAKMT2AMAPTL3MBTL1MEN1
SCHEMBL28058342 0.80 ALDH1A1 (0.49) LMNAKMT2AMAPTL3MBTL1MRGPRX1
SCHEMBL6408139 0.79 LMNA (0.45) LMNAKMT2AMAPTL3MBTL1MEN1
SCHEMBL22967590 0.79 EGFR (0.52) LMNAKMT2AMAPTL3MBTL1MEN1
SCHEMBL6375544 0.76 CTSV (0.60) LMNAKMT2AMAPTL3MBTL1MEN1
SCHEMBL21340751 0.75 EGFR (0.53) LMNAKMT2AMAPTL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154028-A1 Cyclic urea derivatives with 5-ht2c receptor activity GLAXO GROUP LIMITED (GB) 2005-07-14 US disclosed
EP-1465630-A1 CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY GLAXO GROUP LIMITED (GB) 2004-10-13 EP disclosed
WO-2003057220-A1 CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY GLAXO GROUP LIMITED (GB) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154028-A1 Cyclic urea derivatives with 5-ht2c receptor activity HTR2C, HTR3C, HTR5A LMNA 2423/4885KMT2A 3134/4885MAPT 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.